HAIER BIOMEDICAL(688139)2025-04-29 15:43Financial Performance - The company's operating revenue for Q1 2025 was CNY 688,989,400.70, a year-on-year increase of 0.30% and a quarter-on-quarter increase of 37.30%[3]. - Net profit attributable to shareholders decreased by 19.88% year-on-year to CNY 110,258,240.35, while the net profit excluding non-recurring gains and losses fell by 25.38% to CNY 99,168,300.25[3]. - Total revenue for Q1 2025 reached ¥688,989,400.70, a slight increase from ¥686,909,061.52 in Q1 2024, representing a growth of approximately 0.31%[21]. - Net profit for Q1 2025 was ¥116,197,969.19, compared to ¥141,852,238.97 in Q1 2024, reflecting a decrease of approximately 18.1%[22]. - The total comprehensive income for Q1 2025 was ¥116,655,247.96, down from ¥141,864,993.51 in Q1 2024, reflecting a decrease of about 17.73%[22]. - Basic and diluted earnings per share for Q1 2025 were both CNY 0.35, down from CNY 0.44 in Q1 2024, indicating a decrease of approximately 20.45% year-over-year[23]. Cash Flow - The net cash flow from operating activities dropped significantly by 51.79% to CNY 37,219,201.54 compared to the previous year[3][13]. - Cash inflow from operating activities for Q1 2025 was CNY 580,704,504.07, compared to CNY 560,317,919.65 in Q1 2024, reflecting an increase of about 3.46%[24]. - Net cash flow from operating activities decreased to CNY 37,219,201.54 in Q1 2025, down 51.74% from CNY 77,204,996.82 in Q1 2024[24]. - The company reported a total cash outflow from operating activities of CNY 543,485,302.53 in Q1 2025, compared to CNY 483,112,922.83 in Q1 2024, reflecting an increase of about 12.49%[24]. - Cash inflow from investment activities for Q1 2025 was CNY 1,109,537,955.23, significantly higher than CNY 384,384,067.11 in Q1 2024, marking an increase of approximately 188.06%[25]. - Net cash flow from investment activities improved to CNY 82,434,530.50 in Q1 2025, compared to a negative CNY 7,529,404.95 in Q1 2024[25]. - Cash inflow from financing activities totaled CNY 194,362,611.12 in Q1 2025, a substantial increase from CNY 5,170,000.00 in Q1 2024[25]. - The net increase in cash and cash equivalents for Q1 2025 was CNY 102,689,591.57, compared to CNY 50,425,150.14 in Q1 2024, indicating a growth of approximately 103.67%[25]. - The ending balance of cash and cash equivalents as of Q1 2025 was CNY 637,393,622.25, down from CNY 1,307,071,714.34 in Q1 2024[25]. Market Performance - The life sciences segment generated revenue of CNY 354 million, up 1.06% year-on-year and 53.28% quarter-on-quarter[5]. - Domestic market revenue was CNY 482 million, down 3.35% year-on-year but up 54.98% quarter-on-quarter, indicating resilience in a challenging market[6]. - Overseas market revenue reached CNY 204 million, showing a year-on-year growth of 9.88% and a quarter-on-quarter increase of 8.99%[7]. - The market share of the company's biological safety cabinet products has risen to the second brand in the domestic market during Q1 2025[7]. Research and Development - Research and development expenses totaled CNY 80,452,189.16, representing 11.68% of operating revenue, an increase of 0.43 percentage points year-on-year[4]. - Research and development expenses for Q1 2025 were ¥80,452,189.16, compared to ¥77,257,984.27 in Q1 2024, indicating a growth of about 2.85%[21]. Shareholder Information - Total number of common shareholders at the end of the reporting period is 12,793[15]. - The largest shareholder, Qingdao Haier Biomedical Co., Ltd., holds 100,591,463 shares, accounting for 31.64% of the total shares[15]. - The second largest shareholder, Qingdao Haizhi Huiying Equity Investment Management Co., Ltd., holds 32,103,659 shares, representing 10.10% of the total shares[15]. - The company has no changes in the top 10 shareholders due to securities lending activities[17]. Assets and Liabilities - Total current assets as of March 31, 2025, amount to ¥2,314,000,000, a decrease from ¥2,400,000,000 as of December 31, 2024[18]. - Cash and cash equivalents decreased to ¥831,055,160.95 from ¥901,227,075.69[18]. - Accounts receivable increased to ¥431,897,441.94 from ¥323,845,820.79, indicating a growth of approximately 33.5%[18]. - Inventory decreased to ¥303,739,515.42 from ¥334,744,974.95, a decline of about 9.3%[18]. - The company's total assets amounted to ¥5,830,440,601.44, slightly up from ¥5,787,468,795.01 in the previous year[21]. - Total liabilities decreased to ¥1,121,639,324.69 from ¥1,169,332,762.22, showing a reduction of about 4.08%[20]. - The equity attributable to shareholders increased to ¥4,456,255,374.10 from ¥4,371,550,511.01, marking an increase of approximately 1.94%[20]. Operational Conditions - The company has not reported any significant changes in operational conditions during the reporting period[17]. - The company has not disclosed any new strategies or product developments in the current reporting period[17]. - The company did not report any net profit from the merged entity prior to the merger, with previous periods also showing zero net profit[23].